Hemerica

Hemerion Therapeutics is a clinical-stage French biotechnology company developing innovative therapies that combine pharmaceuticals and photonic technology to treat cancer. Their lead solution, PHOSTHERIN, is a drug-device combination designed to eliminate residual cancer cells after surgery, specifically targeting glioblastoma. The technology involves a photosensitizing agent that selectively accumulates in tumor cells, followed by laser illumination to trigger cell death. Hemerion aims to improve survival rates and quality of life for patients with aggressive solid tumors by integrating their treatment into the standard surgical workflow.